Jobs
View more job listings or post a job
How Cancer LLC Social Media Digital Marketing Specialist  
How Cancer LLC Syndicated National Writer - Cancer 
University of California, Davis SCREENING SUPERVISOR
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
Post a job

Symposium

[Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond


Speakers: Oliver Philps, PhD, medicinal chemist; Scott Morano, Ipsos; Roberto Cortese, Ipsos
Organizers: Shichang Miao, PBSS; Dean Wilson, PBSS
Date: 2024-08-22
Time: 11:30-14:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-08-21  (it will close sooner if the seating cap is reached)

About the Topic

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently received significant media coverage for their compelling efficacy in several indications. While most of the recent fanfare has been related to their role in weight loss, GLP-1 receptor agonists have been a mainstay of the type 2 diabetes treatment landscape for the past 2 decades. GLP-1 receptor agonists have also recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases, which has opened the door to potential new indications and label expansions for this drug class. This symposium will explore the evolution of these and other agents (e.g. gastric inhibitory polypeptide [GIP] receptor agonists), including clinical efficacy and safety results, HCP and consumer perspectives, market adoption, and the access, reimbursement, and intellectual property (IP) landscapes. Speakers will include experts in drug discovery and development, and market research.

Symposium topics 

  • Diabetes / obesity and treatments
  • GLP-1 receptor agonists for diabetes and obesity: evolution and current marketed therapies, clinical efficacy and safety
  • GIP receptor agonists and dual GLP-1/GIP receptor agonists
  • Market landscape: revenues, HCP perspectives, consumer viewpoints, access and reimbursement
  • GLP-1 in other indications: CV, kidney disease, MASH
  • On the horizon: the obesity clinical pipeline, IP landscape, and the potential arrival of generics
Time (PST) Topic Presenter
11:30 – 11:45 am PBSS Welcome and Introduction Shichang Miao, PhD, PBSS
11:45 am – 1:00 pm How GLP-1 Receptor Agonists Evolved From Diabetes Treatments to Weight Loss Treatments Oliver Philps, PhD
1:00 – 1:45 pm So Much to Lose: Changing Landscape of Obesity in America Scott Morano, MBA; Roberto Cortese
1:45 – 2:15 pm Panel Discussion Presenters

 


2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
2024-12-05, [Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development
2024-12-13, Why All These New Modalities?
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
2025-02-26, [In-Person] Demystifying Biopharma Business Development
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
©Pharmaceutical & BioScience Society, International; Last Modified: 11/5/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Aroga Biosciences Aroga Biosciences is an award-winning CRO specializing in scientific writing for nonclinical reports, INDs, CMC, and clinical documents.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Aliri Bioanalysis to the rescue! Pioneers in LCMS & Oligo bioanalysis w/ 30+ years of experience putting dev. programs back on track with quality data & fast timelines.
PharmaResources Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Allucent Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
Submit a Text Ad